|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01244 3D MEDICINES
Nominal 
9.070 -0.390 (-4.123%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 209,167 | 1.330% | 445,647 | 634,949 | 567,392 | 60,260 |
| Cost of Sales | (16,260) | -6.942% | (36,572) | (49,091) | (42,215) | (4,277) |
| Gross Profit | 192,907 | 2.095% | 409,075 | 585,858 | 525,177 | 55,983 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (2,903) | -39.153% | (10,057) | 837 | (658,330) | (954,872) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (92,689) | -18.747% | (199,378) | (562,466) | (1,052,030) | (1,461,825) | |
| Taxation | 55 | -- | 0 | (55) | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,284 | -68.916% | 16,715 | 37,824 | 27,680 | 27,733 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (89,350) | -13.679% | (182,663) | (524,697) | (1,024,350) | (1,434,092) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (454) | -58.041% | (1,420) | 1,241 | (4,097) | (3,974) |
| Depreciation & Amortisation | -- | -- | 25,251 | 25,461 | 21,600 | 12,591 |
| Directors' Emoluments | -- | -- | 22,103 | 288,558 | 104,379 | 79,673 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -36.000 | -14.286% | -75.000 | -230.000 | -2,252.000 | -3,672.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.860) | (0.632) | (6.129) | (9.656) |
| NBV per share ($) | 2.774 | -- | 3.040 | 3.628 | 3.689 | -- |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -89,350 |
| %Change | -13.679% |
| EPS / (LPS) | RMB -0.360 |
| NBV Per Share (¥) | RMB 2.774 |